A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis
Public ClinicalTrials.gov record NCT06042920. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Non-Pustular PalmoPlantar and Genital Psoriasis (Psoriatyk Special Sites)
Study identification
- NCT ID
- NCT06042920
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 130 participants
Conditions and interventions
Conditions
Interventions
- Deucravacitinib Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 8, 2023
- Primary completion
- Apr 24, 2025
- Completion
- Apr 24, 2025
- Last update posted
- Apr 16, 2026
2023 – 2025
United States locations
- U.S. sites
- 20
- U.S. states
- 14
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0050 | Phoenix | Arizona | 85006-2722 | — |
| Local Institution - 0015 | Fountain Valley | California | 92708 | — |
| Local Institution - 0009 | Los Angeles | California | 90045-3606 | — |
| Local Institution - 0004 | Santa Monica | California | 90404 | — |
| Local Institution - 0057 | Skokie | Illinois | 60077-1049 | — |
| Local Institution - 0052 | Indianapolis | Indiana | 46250 | — |
| Local Institution - 0053 | Plainfield | Indiana | 46168-2792 | — |
| Local Institution - 0029 | Rockville | Maryland | 20850-6243 | — |
| Local Institution - 0012 | Detroit | Michigan | 48202-3141 | — |
| Local Institution - 0005 | East Windsor | New Jersey | 08520-2505 | — |
| Local Institution - 0002 | New York | New York | 10003 | — |
| Local Institution - 0008 | New York | New York | 10075 | — |
| Local Institution - 0062 | New York | New York | 10128 | — |
| Local Institution - 0001 | Winston-Salem | North Carolina | 27157 | — |
| Local Institution - 0066 | Boardman | Ohio | 44512 | — |
| Local Institution - 0055 | Mayfield Heights | Ohio | 44124-4005 | — |
| Local Institution - 0056 | Pittsburgh | Pennsylvania | 15213-3403 | — |
| Local Institution - 0010 | Houston | Texas | 77004 | — |
| Local Institution - 0007 | Norfolk | Virginia | 23502-3933 | — |
| Local Institution - 0033 | Mill Creek | Washington | 98012-1797 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06042920, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 16, 2026 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06042920 live on ClinicalTrials.gov.